Longeveron Inc (OQ:LGVN)

Business Focus: Biotechnology & Medical Research

May 14, 2024 04:05 pm ET
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31,...
May 10, 2024 04:05 pm ET
Longeveron Announces Board of Directors Planned Transitions
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced planned transitions on its Board of Directors....
May 02, 2024 08:03 am ET
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S....
Apr 25, 2024 04:05 pm ET
Longeveron to Present at the Planet MicroCap Showcase
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s...
Apr 18, 2024 04:05 pm ET
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Apr 17, 2024 08:00 am ET
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Apr 15, 2024 08:30 am ET
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Associatio
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study...
Apr 11, 2024 05:17 pm ET
Longeveron Announces Closing of $5.2 Million Public Offering
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Apr 08, 2024 02:15 pm ET
Longeveron Announces Pricing of $5.25 Million Public Offering
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Apr 08, 2024 08:30 am ET
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Shareholders, I am...
Mar 19, 2024 04:01 pm ET
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse...
Feb 27, 2024 04:05 pm ET
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the year ended December 31, 2023 and provided a corporate...
Feb 21, 2024 04:05 pm ET
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on...
Jan 29, 2024 08:00 am ET
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions , today announces it received a notice of patent allowance...
Dec 22, 2023 04:05 pm ET
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Dec 21, 2023 10:34 am ET
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Dec 21, 2023 08:00 am ET
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Dec 20, 2023 08:00 am ET
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Nov 14, 2023 08:17 am ET
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.
via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to...
Nov 11, 2023 09:00 am ET
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Nov 10, 2023 07:30 am ET
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a...
Nov 03, 2023 08:00 am ET
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023...
Oct 24, 2023 08:30 am ET
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s
via IBN -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured...
Oct 13, 2023 04:05 pm ET
Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Oct 12, 2023 08:00 am ET
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Oct 06, 2023 09:31 am ET
Thinking about buying stock in Camber Energy, RVL Pharmaceuticals, Longeveron, Better Choice Company, or Beneficient?
NEW YORK, Oct. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, RVLP, LGVN, BTTR, and BENF.
Oct 05, 2023 09:31 am ET
Thinking about buying stock in Gaucho Group Holdings, Inhibikase Therapeutics, Energy Transfer LP, Longeveron, or Grom Social Enterprises?
NEW YORK, Oct. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VINO, IKT, ET, LGVN, and GROM.
Oct 05, 2023 07:00 am ET
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Sep 11, 2023 08:00 am ET
Longeveron Issues Letter to Stockholders
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Sep 07, 2023 08:30 am ET
IBN Coverage Initiated for Longeveron Inc.
via IBN – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announced it has selected the...
Sep 07, 2023 08:00 am ET
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Sep 05, 2023 08:00 am ET
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Sep 05, 2023 07:00 am ET
Presenting on the Emerging Growth Conference on September 6 and 7 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with...
Aug 29, 2023 08:00 am ET
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Aug 22, 2023 08:00 am ET
Longeveron Rights Offering Subscription Period Begins
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Aug 16, 2023 09:13 am ET
Longeveron Rights Offering Declared Effective and Calendar Finalized
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Aug 14, 2023 04:05 pm ET
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET. Click...
Aug 14, 2023 08:00 am ET
Longeveron Announces Pricing for Rights Offering and Expected Calendar
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
Aug 11, 2023 07:30 am ET
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate...
Aug 11, 2023 07:00 am ET
Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the Phase 2 ELPIS II trial, funded by the...
Aug 08, 2023 07:00 am ET
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 60th Emerging Growth Conference on August 9, 10, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong...
Aug 07, 2023 08:00 am ET
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023...
Jul 20, 2023 08:00 am ET
Longeveron Appoints Lisa Locklear as Chief Financial Officer
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as...
Jul 11, 2023 08:00 am ET
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M....
Jul 10, 2023 08:00 am ET
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science...
Jun 27, 2023 06:07 pm ET
Longeveron Files Registration Statement for Rights Offering
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as Alzheimer’s Disease and Aging Frailty, announced...
Jun 13, 2023 08:30 am ET
Longeveron Welcomes Three New Prominent Board Members
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the election of three distinguished new...
May 22, 2023 09:00 am ET
The Rosen Law Firm, P.A. Announces Proposed Securities Class Action Settlement on Behalf of Purchasers of the Class A Common Stock of Longeveron Inc. - LGVN
The Rosen Law Firm, P.A. announces that the United States District Court for the Southern District of Florida has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of Longeveron Inc....
May 12, 2023 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the first...
May 09, 2023 08:30 am ET
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
Enrollment ongoing in Phase 2a ELPIS II trial - - Lomecel-BTM has Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation for HLHS Indication - MIAMI, May 09, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:...
May 08, 2023 08:30 am ET
Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its first quarter 2023 financial results on...
Apr 19, 2023 08:59 am ET
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the first patient has been treated with Lomecel-B™ in its Phase 2...
Mar 10, 2023 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter...
Mar 06, 2023 08:30 am ET
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its fourth quarter and full year 2022...
Feb 28, 2023 08:30 am ET
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, and unmet medical needs, today announced the appointment of...
Jan 19, 2023 08:30 am ET
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the publication of the full results from the Company’s ELPIS I trial of...
Jan 06, 2023 09:58 am ET
UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and...
Jan 06, 2023 08:30 am ET
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and...
Nov 29, 2022 04:30 pm ET
Longeveron to Participate in Upcoming 2022 Investor Conferences
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor...
Nov 14, 2022 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the third quarter...
Nov 10, 2022 08:30 am ET
Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM in...
Nov 07, 2022 09:06 am ET
Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on...
Oct 05, 2022 08:30 am ET
Longeveron to Present at the Annual Dawson James Small Cap Growth Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief...
Sep 15, 2022 08:30 am ET
Longeveron Names Jerome Bailey Vice President of Business Operations
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations. He joins the...
Sep 06, 2022 08:30 am ET
Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that Chris Min, M.D., Ph.D., Interim Chief...
Aug 31, 2022 08:30 am ET
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the U.S. Food and Drug Administration (FDA)...
Aug 25, 2022 08:00 am ET
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that the European Patent Office (EPO) has issued a notice of its intent...
Aug 12, 2022 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial...
Aug 08, 2022 08:30 am ET
Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second...
Jul 07, 2022 08:00 am ET
Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer’s...
May 13, 2022 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial...
May 09, 2022 04:15 pm ET
Longeveron Announces CEO Transition
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company") announced today the resignation of Chief Executive Officer (CEO) Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities. Longeveron’s Board of...
May 09, 2022 08:30 am ET
Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first...
Apr 14, 2022 08:58 am ET
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today its Chief Science Officer, Co-Founder, and...
Apr 13, 2022 03:28 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), Coinbase Global, Inc. (NASDAQGS: COIN), HyreCar, Inc. (NASDAQCM: HYRE), and Longeveron Inc. (NASDAQCM: LGVN
Cassava Sciences, Inc. (NASDAQCM: SAVA) Lifshitz Law PLLC announces that a class action complaint was filed against Cassava alleging Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of the...
Apr 13, 2022 08:00 am ET
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development...
Apr 05, 2022 08:00 am ET
Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and other specific life-threatening conditions, announced today the addition of K. Chris...
Mar 31, 2022 08:00 am ET
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1...
Mar 24, 2022 08:00 am ET
Longeveron Presents at Second Euro-Geroscience Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management presented at the Second...
Mar 15, 2022 08:00 am ET
Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...
Mar 11, 2022 08:00 am ET
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Longeveron Inc. (NASDAQ: LGVN) (the “Company,” “Longeveron” or “we,” “us,” or “our”), a clinical stage biopharmaceutical company developing cellular therapies for chronic, aging-related and life-threatening conditions, today reported recent...
Mar 07, 2022 08:00 am ET
Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its fourth...
Mar 02, 2022 08:00 am ET
Longeveron to Present at Q1 Virtual Investor Summit Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...
Feb 17, 2022 08:00 am ET
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its...
Jan 25, 2022 08:00 am ET
Longeveron to Participate in Phacilitate Advanced Therapies Week
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will be speaking and...
Jan 12, 2022 08:00 am ET
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and...
Jan 05, 2022 08:00 am ET
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a...
Jan 05, 2022 07:30 am ET
Thinking about buying stock in Longeveron, Senseonics, Connect Biopharma, Wejo Group, or Energous Corp?
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LGVN, SENS, CNTB, WEJO, and WATT.
Jan 04, 2022 08:00 am ET
Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...
Dec 23, 2021 12:43 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), HyreCar, Inc. (NASDAQCM: HYRE), loanDepot, Inc. (NYSE LDI), and Longeveron Inc. (NASDAQCM: LGVN)
Cassava Sciences, Inc. (NASDAQCM: SAVA) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against Cassava alleging Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity...
Dec 06, 2021 08:00 am ET
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that the U.S. Food and Drug...
Dec 03, 2021 04:30 pm ET
Longeveron Inc. Announces Closing of a $20.5 Million Private Placement
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced...
Dec 03, 2021 09:50 am ET
Thinking about buying stock in DiDi Global, New Oriental Education, Longeveron, Carnival Corp, or Esperion Therapeutics?
NEW YORK, Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, EDU, LGVN, CCL, and ESPR.
Dec 01, 2021 03:16 am ET
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase...
Nov 30, 2021 03:20 pm ET
Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that it has entered into a...
Nov 18, 2021 08:00 am ET
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration...
Nov 12, 2021 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding the status of the...
Nov 10, 2021 01:15 pm ET
NOVEMBER 12, 2021 LAWSUIT DEADLINE REMINDER FOR LONGEVERON INC. (NASDAQ: LGVN) SHAREHOLDERS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Cl
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Nov 09, 2021 03:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline – LGVN
Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) and certain of its officers.   The class action, filed in the United States District Court for the Southern...
Nov 08, 2021 08:30 am ET
Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its third...
Nov 07, 2021 01:15 pm ET
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public offering conducted on or about February 12, 2021 (the “IPO” or “Offering”); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the “Class Period”), of the important November 12, 2021 lead plaintiff deadline.
Nov 05, 2021 03:45 pm ET
IMPORTANT INVESTOR REMINDER - LONGEVERON INC. (NASDAQ: LGVN) LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Act
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Nov 05, 2021 11:00 am ET
Last Few Days to Actively Participate in Longeveron Inc. (LGVN) Class Action - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (b) Longeveron securities between February 12, 2021 and August 12, 2021, inc
Nov 05, 2021 08:30 am ET
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as...
Nov 03, 2021 10:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers.  The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Comp
Nov 03, 2021 09:58 am ET
SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Longeveron Inc. (LGVN)
Shareholder rights law firm Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased Longeveron Inc. (NASDAQ: LGVN) Class A common stock pursuant to or traceable to the Company's February 12, 2021 initial public offering ("IPO"), or between February 12, 2021 and August 12, 2021. Lo
Nov 02, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Longeveron, Boston Beer, Waterdrop, and AppHarvest and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Longeveron Inc. (NASDAQ: LGVN), The Boston Beer Company, Inc. (NYSE: SAM),...
Nov 01, 2021 07:45 pm ET
LGVN SHAREHOLDER ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public offering...
Nov 01, 2021 02:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline – LGVN
Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) and certain of its officers.   The class action, filed in the United States District Court for the Southern...
Nov 01, 2021 01:10 pm ET
IMPORTANT SHAREHOLDER REMINDER - LONGEVERON INC. (NASDAQ: LGVN) LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Oct 27, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Longeveron, Boston Beer, Waterdrop, and AppHarvest and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Longeveron Inc. (NASDAQ: LGVN), The Boston Beer Company, Inc. (NYSE: SAM),...
Oct 27, 2021 05:20 pm ET
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Longeveron, Inc. (NASDAQ: LGVN) and November 12 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against Longeveron, Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) and certain...
Oct 27, 2021 03:45 pm ET
INVESTOR ALERT- LONGEVERON INC. (NASDAQ: LGVN) LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Ag
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Oct 26, 2021 10:00 am ET
SPPI, LDI & LGVN Upcoming Class Action Deadlines - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 25, 2021 11:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers. The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Comp
Oct 22, 2021 05:06 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public...
Oct 21, 2021 03:30 pm ET
INVESTOR ALERT- LONGEVERON INC. (NASDAQ: LGVN) SHAREHOLDER CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class
NEW YORK, Oct. 21, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) from February 9, 2021 through August 12, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Southern District of Florida alleges violations of the Securities Act of 1
Oct 20, 2021 07:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline – LGVN
Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) and certain of its officers.   The class action, filed in the United States District Court for the Southern...
Oct 20, 2021 08:30 am ET
Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the activation of two new clinical sites...
Oct 19, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Longeveron, Boston Beer, Waterdrop, and AppHarvest and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Longeveron Inc. (NASDAQ: LGVN), The Boston Beer Company, Inc. (NYSE: SAM),...
Oct 19, 2021 01:15 pm ET
LONGEVERON INC. (NASDAQ: LGVN) CLASS ACTION LAWSUIT FILING DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Laws
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Oct 17, 2021 10:00 am ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public...
Oct 15, 2021 08:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers. The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Comp
Oct 14, 2021 04:19 pm ET
INVESTOR ALERT- LGVN SHAREHOLDER CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Oct 14, 2021 08:00 am ET
Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...
Oct 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Longeveron, Boston Beer, Waterdrop, and AppHarvest and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Longeveron Inc. (NASDAQ: LGVN), The Boston Beer Company, Inc. (NYSE: SAM),...
Oct 11, 2021 04:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline – LGVN
Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) and certain of its officers.   The class action, filed in the United States District Court for the Southern...
Oct 09, 2021 11:00 am ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public offering conducted on or about February 12, 2021 (the “IPO” or “Offering”); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the “Class Period”), of the important November 12, 2021 lead plaintiff deadline.
Oct 07, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Ventures, Generac, Longeveron, and AppHarvest and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Live Ventures Incorporated (NASDAQ: LIVE), Generac Holdings Inc. (NYSE: GNRC),...
Oct 07, 2021 07:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers.   The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Com
Oct 06, 2021 08:38 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Longeveron, Inc. Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Longeveron, Inc. ("Longeveron" or "the Company") (NASDAQ : LGVN) investors that acquired securities between February 12, 2021 and August 12, 2021....
Oct 06, 2021 12:30 pm ET
LONGEVERON INC. (NASDAQ: LGVN) INVESTOR CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Agai
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Oct 05, 2021 12:30 pm ET
LONGEVERON INC. (NASDAQ: LGVN) INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against t
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) from February 9, 2021 through August 12, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Southern District of Florida alleges violations of the Securities Act of 19
Oct 03, 2021 06:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline – LGVN
Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) and certain of its officers. The class action, filed in the United States District Court for the Southern...
Oct 02, 2021 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Ventures, Generac, Longeveron, and AppHarvest and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Live Ventures Incorporated (NASDAQ: LIVE), Generac Holdings Inc. (NYSE: GNRC),...
Sep 29, 2021 09:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers. The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Com
Sep 29, 2021 10:00 am ET
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced preliminary top line results from ongoing...
Sep 28, 2021 08:00 am ET
Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related, and life-threatening conditions, today announced that the Company’s Lomecel-B research...
Sep 27, 2021 09:21 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Ventures, Generac, and Longeveron and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Live Ventures Incorporated (NASDAQ: LIVE), Generac Holdings Inc. (NYSE: GNRC),...
Sep 27, 2021 03:18 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors With Losses to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public offering...
Sep 24, 2021 09:30 am ET
LGVN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Sep 23, 2021 10:00 am ET
LGVN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Longeveron Inc. Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers, on behalf of shareholders...
Sep 22, 2021 09:02 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Ventures, Generac, and Longeveron and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Live Ventures Incorporated (NASDAQ: LIVE), Generac Holdings Inc. (NYSE: GNRC),...
Sep 21, 2021 08:30 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Longeveron Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public offering...
Sep 21, 2021 08:00 am ET
Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Jorge Ruiz, M.D., Associate Director...
Sep 20, 2021 04:35 pm ET
LONGEVERON INC. (NASDAQ: LGVN) FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Sep 17, 2021 07:23 pm ET
LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of investors that purchased or otherwise acquired Longeveron Inc. (“Longeveron” or the “Company”) (NASDAQ: LGVN) securities pursuant and/or traceable to the offering documents issued in connection with Longeveron’s February 12, 2021 initial public offering (the “IPO”) and/or Longeveron securities between December 18, 2020 and August 10, 2021, both dates inclusive (the “Class Peri
Sep 17, 2021 03:05 pm ET
SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased Longeveron Inc. (NASDAQ: LGVN) Class A common stock pursuant to or traceable to the Company's February 12, 2021 initial public offering ("IPO"), or between February 12, 2021 and August 12, 2021. The
Sep 17, 2021 10:00 am ET
LGVN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Longeveron Inc. Investors of Class Action and Encourages Investors to Contact the Firm
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (b) Longeveron securities be
Sep 16, 2021 05:54 pm ET
LGVN SHAREHOLDER ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Longeveron Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action –
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in...
Sep 16, 2021 05:03 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, Sept. 16, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN) for violations of the federal securities laws.
Sep 15, 2021 04:25 pm ET
LGVN SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against the Longeveron Inc.
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) from February 9, 2021 through August 12, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Southern District of Florida alleges violations of the Securities Act of 1934.
Sep 15, 2021 11:50 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Longeveron Inc. (LGVN)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Longeveron Inc. (NASDAQ: LGVN) in the United States District Court for the Southern District of Florida on behalf of those who purchased Longeveron sotck: (1)...
Sep 15, 2021 08:49 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. (“Longeveron” or “the Company”) (NASDAQ:
Sep 14, 2021 03:02 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. (“Longeveron” or “the Company”) (NASDAQ:
Sep 14, 2021 10:18 am ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LGVN
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company’s initial public offering conducted on or about February 12, 2021 (the “IPO” or “Offering”); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later th
Sep 13, 2021 11:03 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Longeveron Inc. and Certain Officers - LGVN
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers.  The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Co
Sep 13, 2021 09:19 am ET
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing its proprietary product, Lomecel-B, and other cellular therapies for chronic aging-related and life-threatening conditions, has entered...
Sep 09, 2021 08:00 am ET
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the final clinical results from its Phase I...
Sep 01, 2021 08:00 am ET
Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virtually at...
Aug 16, 2021 05:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Longeveron Inc. - LGVN
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Aug 13, 2021 07:00 am ET
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced results from the Company’s Phase 2b trial...
Aug 13, 2021 07:00 am ET
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial...
Aug 10, 2021 08:30 am ET
Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second...
Jul 06, 2021 08:00 am ET
Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the first patient has been enrolled and...
Jun 30, 2021 08:00 am ET
Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B, the...
Jun 24, 2021 08:00 am ET
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for aging-related and chronic disease, announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for...
Jun 15, 2021 08:00 am ET
Longeveron to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...
Jun 10, 2021 08:00 am ET
Longeveron’s Chairman and Chief Science Officer Invited by National Academy of Medicine to Speak at Longevity Symposium
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that its Co-founder and Chairman, Joshua M....
May 25, 2021 09:00 am ET
Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Ursula Ungaro will be joining its...
May 18, 2021 09:00 am ET
Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior...
May 14, 2021 08:00 am ET
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding a number of...
May 11, 2021 09:00 am ET
Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first...
May 05, 2021 09:00 am ET
Longeveron Invited to Present at the Benzinga Global Small Cap Conference
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Chief Executive Officer Geoff Green...
Apr 27, 2021 09:00 am ET
Longeveron Selected to Present at the 2021 World Stem Cell Summit
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World...
Apr 15, 2021 08:30 am ET
Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the completion of the Company’s Phase I/II...
Apr 13, 2021 08:30 am ET
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) announced today the final results of its Phase I clinical study evaluating the safety and efficacy of intravenous (i.v.) administration of Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC)...
Apr 12, 2021 08:00 am ET
SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan
New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, was recently the focus of coverage by leading financial news website and publisher, SmallCapsDaily. Longeveron is swiftly becoming a leader in the biotech and regenerative medicine space, as it continues in its efforts to combat a variety of concerns and illnesses such as aging, Alzheimer's and chronic mental health disorders by engaging in research and development of cellular therapies using stem cells.
Mar 30, 2021 07:00 am ET
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and...
Mar 26, 2021 09:00 am ET
Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a.m....
Mar 19, 2021 07:45 am ET
Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of...
Mar 15, 2021 04:30 pm ET
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previously...
Mar 11, 2021 09:00 am ET
Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration...
Mar 10, 2021 08:30 am ET
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the Company has expanded and amended...
Mar 05, 2021 08:30 am ET
Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that enrollment criteria for its Phase 1...
Mar 03, 2021 08:30 am ET
Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today the completion of the Company’s Phase 2b...
Feb 24, 2021 08:30 am ET
Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, is pleased to announce completion of the Company’s Phase 1...
Feb 19, 2021 08:30 am ET
CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, Chief Executive Officer of...
Feb 18, 2021 08:30 am ET
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D.,...
Feb 11, 2021 10:27 pm ET
Longeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the pricing of an underwritten initial public...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.